RxDoctor Payments DataLook up a doctor →

Angelino Yson, MD

Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1336193465

Payments from drug & device makers

$14,879in general payments, 2019–2025

Across 927 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Amarin Pharma, Inc.$925
  • Amgen$918
  • Boehringer Ingelheim$910
  • Sanofi-aventis U.S. LLC$786
  • plus $8K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk165$2,183
Lilly USA, LLC61$1,007
Amarin Pharma, Inc.61$925
Amgen(2 entities)62$918
Boehringer Ingelheim69$910
Sanofi-aventis U.S. LLC46$786
Abbott38$769
AstraZeneca(2 entities)36$693
Medtronic(2 entities)25$522
Xeris Pharmaceuticals, Inc.23$479
Esperion Therapeutics, Inc.30$450
AbbVie24$440
Corcept Therapeutics28$429
Insulet Corporation23$421
Amneal Pharmaceuticals LLC19$309
Merck18$251
Recordati_rare_diseases_inc.12$240
Antares Pharma, Inc.14$235
Averitas Pharma Inc.9$215
Tandem Diabetes Care, Inc.12$211
Kyowa Kirin, Inc.9$204
Bayer12$179
Ascendis Pharma Endocrinology Inc4$171
Johnson & Johnson23$170
Mannkind Corporation14$156
Radius Health, Inc.9$144
Pfizer7$128
Dexcom, Inc.7$96
Novartis4$80
IBSA Pharma Inc.6$79
Verity Pharmaceuticals Inc.4$76
Sequel Med Tech, LLC3$63
Kowa Pharmaceuticals America, Inc.4$61
BD2$60
Shire North American Group Inc4$59
Embecta Corp.2$58
Zealand Pharma US, Inc.3$58
Madrigal Pharmaceuticals3$56
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$47
Chiesi USA, Inc.3$45
Cequr Corporation1$42
Regeneron Healthcare Solutions, Inc.2$36
Ultragenyx Pharmaceutical Inc.2$33
Neurocrine Biosciences, Inc.1$32
Halozyme Inc1$27
Takeda Pharmaceuticals U.S.A., Inc.2$24
Soleno Therapeutics, Inc.1$23
Almatica Pharma LLC1$23
BETA Bionics, Inc.1$22
EUSA Pharma (US) LLC1$21
Nevro Corp.1$20
Ascensia Diabetes Care US Inc.1$20
Azurity Pharmaceuticals, Inc.1$20
GSK1$19
Vivus LLC1$18
Acella Pharmaceuticals, LLC1$18
Amryt Pharma Holdings Ltd1$17
Therapeuticsmd, Inc.1$16
Lifescan, Inc.1$15
Clarus Therapeutics Inc.1$15

How this compares

$14,879 in reported general payments places this provider in the 75th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

See all endocrinology, diabetes & metabolism providers in Kentucky →

Medicare billing

Part B allowed, 2024
$94,376
Medicare patients
417
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Louisville

See the full list for Kentucky →

Where these figures come from

Is this you, or does something look wrong? →